Pancreatic Cancer Cells Require the Transcription Factor MYRF to Maintain ER Homeostasis

Milan, Marta; Balestrieri, Chiara; Alfarano, Gabriele; Polletti, Sara; Prosperini, Elena; Nicoli, Paola; Scocco, Paola; Zerbi, Alessandro; Cirulli, Vincenzo; Diaferia, Giuseppe R.; Natoli, Gioacchino

doi:10.1016/j.devcel.2020.09.011

Cited by 17 publications

(26 citation statements)

References 68 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…discovered ER stress, inhibited proliferation and inability to form spheroids in vitro in MYRF-deficient pancreatic ductal adenocarcinoma cells. In vivo , the cells formed a less proliferating tumor ( 44 ). Then, PLXNB2 is highly expressed on B cells from germinal center (GC).…”

Section: Discussionmentioning

confidence: 99%

Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines

et al. 2021

View full text Add to dashboard Cite

mRNA vaccines against cancer have advantages in safety, improved therapeutic efficacy, and large-scale production. Therefore, our purpose is to identify immune biomarkers and to analyze immune status for developing mRNA vaccines and selecting appropriate patients for vaccination. We downloaded clinical information and RNA-seq data of 494 LUAD patients from TCGA. LUAD mutational information was hierarchically clustered by NMF package (Version 0.23.0). DeconstructSigs package (Version 1.8.0) and NMF consistency clustering were used to identify mutation signatures. Maftools package (Version 2.6.05) was used to select LUAD-related immune biomarkers. TIMER was used to discuss the correlation between genetic mutations and cellular components. Unsupervised clustering Pam method was used to identify LUAD immune subtypes. Log-rank test and univariate/multivariate cox regression were used to predict the prognosis of immune subtypes. Dimensionality reduction analysis was dedicated to the description of LUAD immune landscape. LUAD patients are classified into four signatures: T >C, APOBEC mutation, age, and tobacco. Then, GPRIN1, MYRF, PLXNB2, SLC9A4, TRIM29, UBA6, and XDH are potential LUAD-related immune biomarker candidates to activate the immune response. Next, we clustered five LUAD-related immune subtypes (IS1–IS5) by prognostic prediction. IS3 showed prolonged survival. The reliability of our five immune subtypes was validated by Thorsson’s results. IS2 and IS4 patients had high tumor mutation burden and large number of somatic mutations. Besides, we identified that immune subtypes of cold immunity (patients with IS2 and IS4) are ideal mRNA vaccination recipients. Finally, LUAD immune landscape revealed immune cells and prognostic conditions, which provides important information to select patients for vaccination. GPRIN1, MYRF, PLXNB2, SLC9A4, TRIM29, UBA6, and XDH are potential LUAD-related immune biomarker candidates to activate the immune response. Patients with IS2 and IS4 might potentially be immunization-sensitive patients for vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines

et al. 2021

View full text Add to dashboard Cite

show abstract

“…DKFZP434K028 is located in the intron antisense of MYRF gene, which encodes a membrane‐bound transcription factor that activates myelin gene through its own proteolysis 36 . Meanwhile, MYRF is involved in maintaining the homeostasis of cancer cells and has potential implications for the biology of tumors 37 . It indicates that the abnormal expression of DKFZP434K028 is indirectly related to the occurrence of tumor.…”

Section: Discussionmentioning

confidence: 99%

Construction of a novel methylation‐related prognostic model for colorectal cancer based on microsatellite status

Cao

Chen

Zhang

et al. 2021

J of Cellular Biochemistry

View full text Add to dashboard Cite

The present study aimed to construct a novel methylation‐related prognostic model based on microsatellite status that may enhance the prognosis of colorectal cancer (CRC) from methylation and microsatellite status perspective. DNA methylation and mRNA expression data with clinical information were downloaded from The Cancer Genome Atlas (TCGA) data set. The samples were divided into microsatellite stability and microsatellite instability group, and CIBERSORT was used to assess the immune cell infiltration characteristics. After identifying the differentially methylated genes and differentially expression genes using R packages, the methylation‐driven genes were further identified. Prognostic genes that were used to establish the methylation‐related risk score model were generated by the univariate and multivariate Cox regression model. Finally, we established and evaluated the methylation‐related prognostic model for CRC patients. A total of 69 MDGs were obtained and three of these genes (MIOX, TH, DKFZP434K028) were selected to construct the prognostic model. Patients in the low‐risk score group had a conspicuously better overall survival than those in the high‐risk score group (p < .0001). The area under the receiver operating characteristic curve for this model was 0.689 at 3 years, 0.674 at 4 years, and 0.658 at 5 years. The Wilcoxon test showed that higher risk score was associated with higher T stage (p = .01), N stages (p = .0028), metastasis (p = .013), and advanced pathological stage (p = .0013). However, the more instability of microsatellite status, the lower risk score of CRC patients (p = .0048). Our constructed methylation‐related prognostic model based on microsatellite status presents potential significance in assessing recurrence risk stratification, tumor staging, and immunotherapy for CRC patients.

show abstract

“…These studies left the impression that Myrf is a "myelin" transcription factor, and hence the name Myrf. It is now clear that MYRF is also expressed in other tissues such as developing diaphragm, heart, stomach, pancreas, and eye (12)(13)(14)(15)(16). Consistently, MYRF mutations have been implicated in both myelin and non-myelin diseases (13)(14)(15)(17)(18)(19)(20), and whole-body Myrf knockout leads to embryonic lethality independent of OL generation (1).…”

Section: Introductionmentioning

confidence: 93%

Functional mechanisms of MYRF DNA-binding domain mutations implicated in birth defects

Fan¹,

An²,

Sharif

et al. 2021

Journal of Biological Chemistry

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Pancreatic Cancer Cells Require the Transcription Factor MYRF to Maintain ER Homeostasis

Cited by 17 publications

References 68 publications

Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines

Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines

Construction of a novel methylation‐related prognostic model for colorectal cancer based on microsatellite status

Functional mechanisms of MYRF DNA-binding domain mutations implicated in birth defects

Contact Info

Product

Resources

About